BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//BioCatalystFeed//bcf//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BioCatalystFeed BEAM catalysts
X-WR-CALDESC:Scheduling/reference data from public records\; dates can move
 . Not investment\, legal or medical advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:e26bc499e3fe81bcae39@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:BEAM P1/P2 readout (est.): A Study Evaluating the Safety and Effica
 cy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia 
 (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)
DESCRIPTION:A Study Evaluating the Safety and Efficacy of BEAM-201 in Relap
 sed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymph
 oblastic Lymphoma (T-LL)\nNCT05885464 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUIT
 ING | sponsor: Beam Therapeutics Inc.\nPrimary completion date (ESTIMATED)
 \; top-line results usually follow later.\nDate precision: month (shown on
  the first day)\nTicker BEAM (confidence 0.9)\nSource: https://clinicaltri
 als.gov/study/NCT05885464\nScheduling/reference data from public records\;
  dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05885464
CATEGORIES:readout,ESTIMATED
END:VEVENT
END:VCALENDAR
